Literature DB >> 26453362

Electroclinical Features of Early-Onset Epileptic Encephalopathies in Congenital Disorders of Glycosylation (CDGs).

Agata Fiumara1, Rita Barone2,3, Giuliana Del Campo4, Pasquale Striano5, Jaak Jaeken6.   

Abstract

Congenital disorders of glycosylation (CDG) are a constantly growing group of genetic defects of glycoprotein and glycolipid glycan synthesis. CDGs are usually multisystem diseases, and in the majority of patients, there is an important neurological involvement comprising psychomotor disability, hypotonia, ataxia, seizures, stroke-like episodes, and peripheral neuropathy. To assess the incidence, among early-onset epileptic encephalopathies (EOEE), of patients with identified congenital disorders of glycosylation (CDG), we made a review of clinical, electrophysiological, and neuroimaging findings of 27 CDG patients focusing on seizure onset, semiology and frequency, response to antiepileptic drugs (AED), and early epileptic manifestations. Epilepsy was uncommon in PMM2-CDG (11%), while it was a main concern in other rare forms. We describe a series of patients with EOEE and genetically confirmed CDG (ALG3-CDG, ALG6-CDG, DPM2-CDG, ALG1-CDG). Epileptic seizures at onset included myoclonic and clonic fits and focal seizures. With time, patients developed recurrent and intractable seizures principally tonic-clonic seizures, infantile spasms, and myoclonic seizures. Electrophysiological correlates included focal and multifocal epileptic discharges, slowed background rhythm, and generalized epileptic activity including burst suppression pattern and status epilepticus. We propose a diagnostic flowchart for the early diagnosis of CDG in patients presenting with EOEE and suggest to perform serum transferrin IEF (or capillary zone electrophoresis) as a first-line screening in early-onset epilepsy.

Entities:  

Keywords:  ALG1-CDG; ALG3-CDG; ALG6-CDG; Congenital disorders of glycosylation; DPM2-CDG; Epilepsy

Year:  2015        PMID: 26453362      PMCID: PMC4867844          DOI: 10.1007/8904_2015_497

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  18 in total

Review 1.  Genetic defects in the human glycome.

Authors:  Hudson H Freeze
Journal:  Nat Rev Genet       Date:  2006-06-06       Impact factor: 53.242

2.  ALG3-CDG (CDG-Id): clinical, biochemical and molecular findings in two siblings.

Authors:  Suzi Riess; Dinah Susan Reddihough; Katherine Brooke Howell; Charuta Dagia; Jaak Jaeken; Gert Matthijs; Joy Yaplito-Lee
Journal:  Mol Genet Metab       Date:  2013-06-07       Impact factor: 4.797

3.  De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy.

Authors:  Hirofumi Kodera; Kazuyuki Nakamura; Hitoshi Osaka; Yoshihiro Maegaki; Kazuhiro Haginoya; Shuji Mizumoto; Mitsuhiro Kato; Nobuhiko Okamoto; Mizue Iai; Yukiko Kondo; Kiyomi Nishiyama; Yoshinori Tsurusaki; Mitsuko Nakashima; Noriko Miyake; Kiyoshi Hayasaka; Kazuyuki Sugahara; Isao Yuasa; Yoshinao Wada; Naomichi Matsumoto; Hirotomo Saitsu
Journal:  Hum Mutat       Date:  2013-10-15       Impact factor: 4.878

4.  Clinical utility gene card for: ALG6 defective congenital disorder of glycosylation.

Authors:  Jaak Jaeken; Dirk Lefeber; Gert Matthijs
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

5.  Carbohydrate-deficient glycoprotein syndrome: normal glycosylation in the fetus.

Authors:  P Clayton; B Winchester; E Di Tomaso; E Young; G Keir; C Rodeck
Journal:  Lancet       Date:  1993-04-10       Impact factor: 79.321

Review 6.  Genes of early-onset epileptic encephalopathies: from genotype to phenotype.

Authors:  Mario Mastrangelo; Vincenzo Leuzzi
Journal:  Pediatr Neurol       Date:  2012-01       Impact factor: 3.372

7.  ALG1-CDG: a new case with early fatal outcome.

Authors:  A-K Rohlfing; S Rust; J Reunert; M Tirre; I Du Chesne; Sa Wemhoff; F Meinhardt; H Hartmann; A M Das; T Marquardt
Journal:  Gene       Date:  2013-10-21       Impact factor: 3.688

8.  Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation.

Authors:  Bobby G Ng; Kati J Buckingham; Kimiyo Raymond; Martin Kircher; Emily H Turner; Miao He; Joshua D Smith; Alexey Eroshkin; Marta Szybowska; Marie E Losfeld; Jessica X Chong; Mariya Kozenko; Chumei Li; Marc C Patterson; Rodney D Gilbert; Deborah A Nickerson; Jay Shendure; Michael J Bamshad; Hudson H Freeze
Journal:  Am J Hum Genet       Date:  2013-04-04       Impact factor: 11.025

Review 9.  Congenital disorders of glycosylation with emphasis on cerebellar involvement.

Authors:  Rita Barone; Agata Fiumara; Jaak Jaeken
Journal:  Semin Neurol       Date:  2014-09-05       Impact factor: 3.420

10.  29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype.

Authors:  Marie-Lorraine Monin; Cyril Mignot; Pascale De Lonlay; Bénédicte Héron; Alice Masurel; Michèle Mathieu-Dramard; Catherine Lenaerts; Christel Thauvin; Marion Gérard; Emmanuel Roze; Aurélia Jacquette; Perrine Charles; Claire de Baracé; Valérie Drouin-Garraud; Philippe Khau Van Kien; Valérie Cormier-Daire; Michèle Mayer; Hélène Ogier; Alexis Brice; Nathalie Seta; Delphine Héron
Journal:  Orphanet J Rare Dis       Date:  2014-12-11       Impact factor: 4.123

View more
  9 in total

1.  ALG3-CDG: lethal phenotype and novel variants in Chinese siblings.

Authors:  Yue Bian; Chong Qiao; ShuGuang Zheng; Hao Qiu; Huan Li; ZhiTao Zhang; ShaoWei Yin; HongKun Jiang; Jesse Li-Ling; CaiXia Liu; Yuan Lyu
Journal:  J Hum Genet       Date:  2020-07-12       Impact factor: 3.172

2.  Arrest of Fetal Brain Development in ALG11-Congenital Disorder of Glycosylation.

Authors:  Sarah B Mulkey; Bobby G Ng; Gilbert L Vezina; Dorothy I Bulas; Lynne A Wolfe; Hudson H Freeze; Carlos R Ferreira
Journal:  Pediatr Neurol       Date:  2018-12-24       Impact factor: 3.372

3.  Complex Neurological Phenotype Associated with a De Novo DHDDS Mutation in a Boy with Intellectual Disability, Refractory Epilepsy, and Movement Disorder.

Authors:  Gianluca Piccolo; Elisabetta Amadori; Maria Stella Vari; Francesca Marchese; Antonella Riva; Valentina Ghirotto; Michele Iacomino; Vincenzo Salpietro; Federico Zara; Pasquale Striano
Journal:  J Pediatr Genet       Date:  2020-07-31

4.  Successful treatment of intractable epilepsy with ketogenic diet therapy in twins with ALG3-CDG.

Authors:  C Paketci; P Edem; S Hiz; E Sonmezler; D Soydemir; G Sarikaya Uzan; Y Oktay; E O'Heir; S Beltran; S Laurie; A Töpf; H Lochmuller; R Horvath; U Yis
Journal:  Brain Dev       Date:  2020-05-07       Impact factor: 1.961

5.  Expanding the phenotype, genotype and biochemical knowledge of ALG3-CDG.

Authors:  Hind Alsharhan; Bobby G Ng; Earnest James Paul Daniel; Jennifer Friedman; Eniko K Pivnick; Amal Al-Hashem; Eissa Ali Faqeih; Pengfei Liu; Nicole M Engelhardt; Kierstin N Keller; Jie Chen; Pamela A Mazzeo; Jill A Rosenfeld; Michael J Bamshad; Deborah A Nickerson; Kimiyo M Raymond; Hudson H Freeze; Miao He; Andrew C Edmondson; Christina Lam
Journal:  J Inherit Metab Dis       Date:  2021-03-01       Impact factor: 4.750

6.  Clinical, biochemical and molecular phenotype of congenital disorders of glycosylation: long-term follow-up.

Authors:  Anna Bogdańska; Patryk Lipiński; Paulina Szymańska-Rożek; Aleksandra Jezela-Stanek; Dariusz Rokicki; Piotr Socha; Anna Tylki-Szymańska
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

Review 7.  Congenital Disorders of Glycosylation from a Neurological Perspective.

Authors:  Justyna Paprocka; Aleksandra Jezela-Stanek; Anna Tylki-Szymańska; Stephanie Grunewald
Journal:  Brain Sci       Date:  2021-01-11

Review 8.  ALG3-CDG: a patient with novel variants and review of the genetic and ophthalmic findings.

Authors:  Martina Farolfi; Anna Cechova; Nina Ondruskova; Jana Zidkova; Bohdan Kousal; Hana Hansikova; Tomas Honzik; Petra Liskova
Journal:  BMC Ophthalmol       Date:  2021-06-05       Impact factor: 2.209

Review 9.  Inborn Errors of Metabolism and Epilepsy: Current Understanding, Diagnosis, and Treatment Approaches.

Authors:  Suvasini Sharma; Asuri N Prasad
Journal:  Int J Mol Sci       Date:  2017-07-02       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.